Erwan Dewel
GDC Technology Lead Patient Solutions at UCB | Brussels Metropolitan Area, Belgium
Erwan Dewel’s Email & Phone Number
VerifiedFree account · No credit card · 5 profiles/month
ContactOut Insights • AI Generated
Erwan Dewel serves as the GDC Technology Lead for Patient Solutions at UCB, an organization dedicated to supporting individuals affected by severe central nervous system and immunological conditions. Operating from the Brussels Metropolitan Area within the information technology and services sector, he directs technical strategy for patient-centered digital initiatives. He holds his educational background from I.S.F.C.E. and leverages that foundation to align healthcare delivery with modern technological innovations.
BEST APPROACH TO REACH Erwan Dewel
Send a direct LinkedIn message proposing a brief consultation on aligning your offerings with UCB’s patient solution technologies, leveraging the directory’s strong indicators for work-focused communication channels.
GDC Technology Lead Patient Solutions at UCB in September 2025 - Present
Developer Experience at DPG Media IT in September 2023 - September 2025
AWS Solution Architect Tech Leader at Devoteam A Cloud in September 2022 - September 2023
Senior Manager at Baxter International Inc. in February 2022 - September 2022
Cloud Solution Architect at Baxter International Inc. in November 2017 - February 2022
IT Infrastructure Architect at NRB in November 2016 - November 2017
ICT Delivery Team Leader at I.R.I.S. ICT in April 2015 - November 2016
Technical Consultant / Pre-Sales at I.R.I.S. ICT in August 2013 - April 2015
IT Specialist at IBM in March 2012 - August 2013
Technical Consultant at I.R.I.S. ICT in January 2008 - October 2012
Linux System Engineer at Smals in July 2005 - January 2008
I.S.F.C.E., Bachelor of Information Technology, July 2026
At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.
Discover more about UCB
Head of Business Excellence, Patient Supply at UCB
Sr Director, Head of Business Excellence at UCB
(September 2024 – Present)
Senior Project Leader
Senior Project Leader at UCB
(June 2025 – Present)
Head of Clinical Supply Chain
Head of Clinical Supply Chain at UCB
(September 2024 – Present)
Global TA&L Launch Excellence Lead
Global TA&L Launch Excellence Lead at UCB
(June 2022 – Present)
Head of Safety Histology | PhD
Senior Scientist at UCB
(October 2020 – Present)
Gene Therapy Process Engineering Lead
Gene Therapy Process Engineering Lead at UCB
(September 2024 – Present)
What is Erwan Dewel email address?
Email Erwan Dewel at [email protected] and [email protected]. This email is the most updated Erwan Dewel's email found in 2026.
How to contact Erwan Dewel?
To contact Erwan Dewel send an email to [email protected] or [email protected]. (updated on November 08, 2025)
What company does Erwan Dewel work for?
Erwan Dewel works for UCB.
What is Erwan Dewel's role at UCB?
Erwan Dewel is GDC Technology Lead Patient Solutions
What industry does Erwan Dewel work in?
Erwan Dewel works in the Information Technology & Services industry.
